Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 6.08 billion. The enterprise value is 5.60 billion.
| Market Cap | 6.08B |
| Enterprise Value | 5.60B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 223.04 million shares outstanding. The number of shares has increased by 5.56% in one year.
| Current Share Class | 223.04M |
| Shares Outstanding | 223.04M |
| Shares Change (YoY) | +5.56% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | n/a |
| Float | 37.17M |
Valuation Ratios
The trailing PE ratio is 32.64.
| PE Ratio | 32.64 |
| Forward PE | n/a |
| PS Ratio | 4.30 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 2.76 |
| P/FCF Ratio | 24.70 |
| P/OCF Ratio | 19.79 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.74, with an EV/FCF ratio of 22.77.
| EV / Earnings | 28.50 |
| EV / Sales | 3.96 |
| EV / EBITDA | 14.74 |
| EV / EBIT | 22.73 |
| EV / FCF | 22.77 |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.07.
| Current Ratio | 8.15 |
| Quick Ratio | 5.81 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.78 |
| Interest Coverage | 41.06 |
Financial Efficiency
Return on equity (ROE) is 8.85% and return on invested capital (ROIC) is 9.83%.
| Return on Equity (ROE) | 8.85% |
| Return on Assets (ROA) | 5.62% |
| Return on Invested Capital (ROIC) | 9.83% |
| Return on Capital Employed (ROCE) | 8.84% |
| Weighted Average Cost of Capital (WACC) | 4.66% |
| Revenue Per Employee | 8.18M |
| Profits Per Employee | 1.14M |
| Employee Count | 173 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, Orient Pharma has paid 34.73 million in taxes.
| Income Tax | 34.73M |
| Effective Tax Rate | 15.02% |
Stock Price Statistics
The stock price has decreased by -24.76% in the last 52 weeks. The beta is 0.09, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -24.76% |
| 50-Day Moving Average | 25.21 |
| 200-Day Moving Average | 25.58 |
| Relative Strength Index (RSI) | 64.50 |
| Average Volume (20 Days) | 449,896 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.41 billion and earned 196.58 million in profits. Earnings per share was 0.83.
| Revenue | 1.41B |
| Gross Profit | 810.50M |
| Operating Income | 246.49M |
| Pretax Income | 231.31M |
| Net Income | 196.58M |
| EBITDA | 361.16M |
| EBIT | 246.49M |
| Earnings Per Share (EPS) | 0.83 |
Balance Sheet
The company has 666.69 million in cash and 191.92 million in debt, with a net cash position of 474.77 million or 2.13 per share.
| Cash & Cash Equivalents | 666.69M |
| Total Debt | 191.92M |
| Net Cash | 474.77M |
| Net Cash Per Share | 2.13 |
| Equity (Book Value) | 2.60B |
| Book Value Per Share | 10.71 |
| Working Capital | 1.13B |
Cash Flow
In the last 12 months, operating cash flow was 307.12 million and capital expenditures -61.11 million, giving a free cash flow of 246.01 million.
| Operating Cash Flow | 307.12M |
| Capital Expenditures | -61.11M |
| Depreciation & Amortization | 114.67M |
| Net Borrowing | -333.49M |
| Free Cash Flow | 246.01M |
| FCF Per Share | 1.10 |
Margins
Gross margin is 57.29%, with operating and profit margins of 17.42% and 13.90%.
| Gross Margin | 57.29% |
| Operating Margin | 17.42% |
| Pretax Margin | 16.35% |
| Profit Margin | 13.90% |
| EBITDA Margin | 25.53% |
| EBIT Margin | 17.42% |
| FCF Margin | 17.39% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.56% |
| Shareholder Yield | -5.56% |
| Earnings Yield | 3.23% |
| FCF Yield | 4.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 12.4 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.4 |
| Piotroski F-Score | 6 |